These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21378351)

  • 1. The need for third-line treatment in non-small cell lung cancer: an overview of new options.
    Syrigos KN; Saif MW; Karapanagiotou EM; Oikonomopoulos G; De Marinis F
    Anticancer Res; 2011 Feb; 31(2):649-59. PubMed ID: 21378351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
    Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
    Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
    Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New avenues for second-line treatment of metastatic non-small-cell lung cancer.
    Gridelli C; Maione P; Rossi A; Falanga M; Bareschino M; Schettino C; Colantuoni G; Guerriero C; Nicolella D; Rossi E; Ferrara ML; Palazzolo G
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):115-24. PubMed ID: 19105711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
    Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
    Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
    Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.
    Vázquez S; Lázaro M; Fírvida JL; Santomé L; Afonso J; Amenedo M; Casal J;
    Anticancer Drugs; 2014 Apr; 25(4):368-74. PubMed ID: 24384805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line therapeutic options in non-small-cell lung cancer.
    Vansteenkiste J
    Lung Cancer; 2006 Dec; 54 Suppl 2():S15-8. PubMed ID: 17064813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
    Custodio A; de Castro J
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
    Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
    Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
    Ramalingam S; Sandler AB
    Oncologist; 2006 Jun; 11(6):655-65. PubMed ID: 16794244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations for second-line therapy of non-small cell lung cancer.
    Stinchcombe TE; Socinski MA
    Oncologist; 2008; 13 Suppl 1():28-36. PubMed ID: 18263772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
    Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA
    J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pemetrexed salvage chemotherapy for NSCLC: implementation study].
    Jungels C; Berghmans T; Meert AP; Lafitte JJ; Scherpereel A; Sculier JP
    Rev Mal Respir; 2012 Jan; 29(1):21-7. PubMed ID: 22240216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.
    de Marinis F; De Santis S; De Petris L
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S17-24. PubMed ID: 16472705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
    Chang MH; Ahn JS; Lee J; Kim KH; Park YH; Han J; Ahn MJ; Park K
    Lung Cancer; 2010 Sep; 69(3):323-9. PubMed ID: 20061047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.